Essay Undergraduate 1,013 words

Bayer's Cipro Patent Ethics During the Anthrax Crisis

~6 min read

Abstract

This paper examines the ethical and corporate dilemma Bayer faced regarding its patent on Cipro during the post-9/11 anthrax scare. Drawing on utilitarian and consequentialist ethical frameworks, the paper argues that Bayer should have voluntarily and temporarily suspended its patent to build public goodwill while protecting long-term shareholder value. The analysis also addresses Bayer's labeling responsibilities under FDA guidelines and the broader legitimacy of pharmaceutical patent protection in the United States. The paper concludes that voluntary patent suspension, combined with strong consumer safety messaging aligned with CDC recommendations, represented the most strategically and ethically sound course of action available to the company.

Key Takeaways

Introduction: Shareholder Interests and Corporate Ethics: Framing Bayer's decision around patents and ethics
Ethical Frameworks and the Cipro Patent Dilemma: Utilitarian and consequentialist views on patent release
The Case for Voluntary Patent Suspension: Goodwill and shareholder benefits of suspending patent
Labeling Responsibilities and Consumer Safety: FDA compliance and boosted Cipro consumer warnings
The Legitimacy of Pharmaceutical Patent Profits: Moral legitimacy of profiting from public health crises
Conclusion and Recommended Course of Action: Final recommendation for decisive Bayer leadership

Cipro Patent Patent Suspension Utilitarian Ethics Consequentialist Ethics Shareholder Value Public Goodwill Pharmaceutical Patents Consumer Labeling Monopoly Rents Anthrax Crisis

This study guide is drawn from PaperDue's library of 130,000+ paper examples across 47 subjects.

📝 How to Write This Type of Paper Writing guide — click to expand

▼

What makes this paper effective

The paper applies named ethical frameworks — utilitarianism and consequentialism — directly to a concrete corporate decision, grounding abstract theory in a real-world scenario.
It balances competing stakeholder interests (shareholders, the public, government regulators) without dismissing any perspective, which strengthens the credibility of its conclusion.
The use of a legal precedent (Wyeth v. Levine) and academic sources on patent theory adds disciplinary breadth appropriate for a business ethics argument.

Key academic technique demonstrated

The paper demonstrates applied ethical reasoning — the practice of selecting and deploying established normative frameworks to evaluate a specific business decision. Rather than merely describing what happened, the author tests the situation against both utilitarian and consequentialist lenses and shows where they converge, lending logical force to the final recommendation.

Structure breakdown

The paper opens by defining the decision context (shareholder vs. ethical obligations), then moves through competing ethical frameworks, arrives at a policy recommendation (voluntary suspension), and addresses ancillary operational issues (labeling, CDC compliance). It closes with a concise summary reiterating the core recommendation. This problem–analysis–recommendation structure is characteristic of applied business ethics writing at the undergraduate level.

Writing help for this paper

Introduction: Shareholder Interests and Corporate Ethics

Bayer must make its decision on an appropriate course of action in the context of two key variables: shareholder interests and corporate ethics. Bayer's indecision was the worst of both worlds — it resulted in considerable erosion of goodwill, and a suspension of the patent would not have been in the best interests of shareholders under a reactive, forced scenario. Patents exist to protect intellectual property, and this holds even in the event of a public health crisis. Bayer has an obligation to protect its intellectual property rights because doing so serves the interests of shareholders. The only reason not to uphold these property rights is if doing so would create such a negative public perception of the company as to damage the business in the long run.

From an ethical perspective, the concern is not merely the perception of profiting from a crisis. Utilitarian ethics would demand that if releasing the Cipro patent were the moral imperative, it should be released. Determining the moral imperative, however, is the role of management and is shaped by societal norms. Consequentialist ethics would view the issue as one in which putting profit over public health is a risky proposition for Bayer. If the company were unable to meet the demand for Cipro, it would be roundly criticized and face a profound erosion of goodwill.

Ethical Frameworks and the Cipro Patent Dilemma

Moreover, from a long-run consequentialist perspective, protecting patents encourages innovation by providing the opportunity for monopoly rents. The system, therefore, should not be broken in response to public panic; while politically expedient, such moves discourage innovation (Sterckx, 2006). Bayer therefore faces a genuine ethical dilemma.

Given that the market in question is the United States, the moral imperative is defined by the American people. In this society, drug patents and intellectual property are held in high esteem, but the health of the community is also held in high regard. Sacrificing short-term profits to help the community is something that would be viewed favorably — and for many Americans, it would be considered the correct course of action. Given that consequentialist ethics supports the utilitarian view that Bayer should temporarily release its patent on Cipro, that is the course of action the company should take.

The Case for Voluntary Patent Suspension

In voluntarily suspending the patent, Bayer achieves two key objectives. The first is that it demonstrates considerable good faith — that under the circumstances, a temporary suspension would not be abused by competitors. This demonstration of good faith and an interest in the public good can only benefit the company in terms of goodwill, both with governments facing a perceived health crisis and among a fearful populace.

The second objective is to build shareholder value. Shareholders lose in the short term because Bayer loses its pricing power on Cipro and because potential sales volumes are reduced. However, shareholders benefit in the long run from the goodwill that the gesture generates. The shareholders were never anticipating a massive run on Cipro, so they are not sacrificing expected profits. The lesson Bayer learned in the wake of World War Two was the value of goodwill with governments. By voluntarily helping to solve their problems, Bayer can avoid circumstances like the aspirin debacle by building a stockpile of goodwill to be drawn upon later.

2 Locked Sections · 260 words remaining

Labeling Responsibilities and Consumer Safety · 130 words

"FDA compliance and boosted Cipro consumer warnings"

The Legitimacy of Pharmaceutical Patent Profits · 130 words

"Moral legitimacy of profiting from public health crises"

Unlock these 2 sections →

Conclusion and Recommended Course of Action

Bayer needs to be more decisive and take leadership on this issue. There is nothing wrong with continuing to extract monopoly rents on patent-protected products. However, community standards suggest that it may be better to voluntarily suspend the patent. This will generate considerable goodwill within the community — goodwill that could prove valuable at a later date. In addition to suspending the patent, Bayer should back the CDC's warnings about the use of Cipro. The company should also boost its labeling to protect itself against product misuse, the likelihood of which has increased in light of the public panic.

You’re 62% through this paper. Sign up to read the remaining 2 sections.

130,000+ paper examples AI writing assistant Citation generator Cancel anytime

Key Concepts in This Paper

Cipro Patent Patent Suspension Utilitarian Ethics Consequentialist Ethics Shareholder Value Public Goodwill Pharmaceutical Patents Consumer Labeling Monopoly Rents Anthrax Crisis